Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

Autor: Rachael Batteson, Stéphane Roze, Kyna Gooden, Srividya Kotapati, Rose Hart, Matthew Hemstock, Adenike Amadi, Dawn Lee

Publikováno v: PharmacoEconomics Open

Introduction Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data were av

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1cd839d81bbf5361fee6d6ea2049cc
https://doi.org/10.1007/s41669-019-00181-y

The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations

Autor: Neil Roskell, Antje Teubner, Michael Taylor, Arun Abraham, Simon Lal, Sorrel Burden, Matthew Hemstock, Alasdair MacCulloch

Publikováno v: Burden, S, Hemstock, M, Taylor, M, Teubner, A, Roskell, N, Macculloch, A, Abraham, A & Lal, S 2018, ' The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations ', Clinical Nutrition ESPEN . https://doi.org/10.1016/j.clnesp.2018.07.006

Home parenteral nutrition (HPN) provides fluid and nutrition essential for the survival of patients with type 3 intestinal failure (IF). However, it is associated with complications and re-admission to hospital. This study aims to investigate the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6274f7ac0d3358484194e08a4eec79d5
https://linkinghub.elsevier.com/retrieve/pii/S2405457718301050